Check out our exclusive interviews with Takeda's Dr. Tachi Yamada and RIKEN's Professor Masayo Takahashi in the April 2015 print magazine!
The research alliance between Monash and Takeda will investigate nano-medicine for gastrointestinal diseases, among other projects.
GE Healthcare's MR elastography technology will aid researchers in non-invasively assessing liver stiffness in the search for new drugs.
Alfresa's Vaccine Scheduling System helps parents keep track of their children's increasingly complex vaccination schedules.
BioMotiv and Takeda pharmaceutical company enter into a strategic partnership to identify and develop pioneering medical innovations.
Research in the neglected tropical diseases of dengue, malaria and Chagas disease receive a US$15.3 million boost in funding from GHIT.
The partnership between Sanofi and Takeda aims to raise diabetes awareness and provide educational support for both patients and healthcare professionals.
MGD010, which simultaneously targets the cell surface receptors CD32B and CD78B, could help modulate B cell function without causing depletion.
Developed using cell culture-based technology, Takeda's H5N1 vaccine could help to strengthen Japan's pandemic preparedness.